Catalyst Pharmaceuticals Files 8-K on Director, Officer, and Compensation Changes

Ticker: CPRX · Form: 8-K · Filed: May 23, 2025 · CIK: 1369568

Catalyst Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyCatalyst Pharmaceuticals, Inc. (CPRX)
Form Type8-K
Filed DateMay 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

Related Tickers: CPRX

TL;DR

Catalyst Pharma 8-K: Board shakeup, exec pay changes, and shareholder votes filed May 20.

AI Summary

Catalyst Pharmaceuticals, Inc. announced on May 20, 2025, changes in its board of directors and executive compensation arrangements. The company also reported on matters submitted for a vote by its security holders. Specific details regarding the director changes, officer appointments, and compensation adjustments were filed in this 8-K report.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty, but the filing itself is a routine disclosure.

Key Players & Entities

  • CATALYST PHARMACEUTICALS, INC. (company) — Filer
  • May 20, 2025 (date) — Date of Earliest Event Reported
  • Delaware (jurisdiction) — State of Incorporation

FAQ

What specific changes were made to the board of directors?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not detail the specific individuals or changes within this summary.

What are the key details of the compensatory arrangements mentioned?

The filing notes 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not provided in the summary text.

What matters were submitted to a vote of security holders?

The filing states 'Submission of Matters to a Vote of Security Holders' as an item of information, but the nature of these matters is not specified in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 20, 2025.

What is Catalyst Pharmaceuticals, Inc.'s standard industrial classification?

Catalyst Pharmaceuticals, Inc.'s standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding CATALYST PHARMACEUTICALS, INC. (CPRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.